Palbociclib

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[1][2] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.[3] Contents 1 Mechanism of action 2 Administration 3 Approvals and indications 3.1 HR+ breast cancer 4 Adverse effects 5 ... [wikipedia]